Literature DB >> 18784340

Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.

Dominic F Kelly1, E Richard Moxon, Ly-Mee Yu, Andrew J Pollard.   

Abstract

The introduction of routine infant immunization with Haemophilus influenzae type b (Hib) conjugate vaccines in the United Kingdom in 1992 led to a significant reduction in invasive disease due to this organism. Subsequently, between 1999 and 2003 there was an increase in the number of immunized children with Hib infection. We investigated whether the rise in cases was related to changes in anti-polyribosylribitol phosphate (PRP) antibody concentration or avidity. Using stored sera, we analyzed temporal changes in antibody levels among 3- to 5-year-old children immunized between 1991 and 2000. Anti-PRP antibody concentrations were higher in 3- to 5-year-olds who received infant immunization in 1991 than those in subsequent years. This difference may be related to changes in either the mode of administration of Hib conjugate vaccines or the rates of Hib nasopharyngeal carriage. This study emphasizes the factors affecting anti-PRP antibody concentration following immunization with conjugate vaccines and the importance of these in long-term protection from invasive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784340      PMCID: PMC2643546          DOI: 10.1128/CVI.00023-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

Review 1.  Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.

Authors:  J Eskola; J Ward; R Dagan; D Goldblatt; F Zepp; C A Siegrist
Journal:  Lancet       Date:  1999-12-11       Impact factor: 79.321

Review 2.  Assessing efficacy of Haemophilus influenzae type b combination vaccines.

Authors:  D M Granoff
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

3.  Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

Authors:  J McVernon; P D R Johnson; A J Pollard; M P E Slack; E R Moxon
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

4.  Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.

Authors:  J McVernon; N Andrews; M P E Slack; M E Ramsay
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

5.  Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign.

Authors:  C L Trotter; M E Ramsay; M P E Slack
Journal:  Commun Dis Public Health       Date:  2003-04

6.  Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed.

Authors:  Mijke A Breukels; Els Jol-van der Zijde; Maarten J D van Tol; Ger T Rijkers
Journal:  Clin Infect Dis       Date:  2001-12-07       Impact factor: 9.079

7.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.

Authors:  P T Heath; R Booy; H J Azzopardi; M P Slack; J Bowen-Morris; H Griffiths; M E Ramsay; J J Deeks; E R Moxon
Journal:  JAMA       Date:  2000-11-08       Impact factor: 56.272

8.  Immunogenicity and safety in infants of a DTwPHib full liquid vaccine.

Authors:  F I Botet Asensi; A Veronese; M Del Carmen Otero; M Desamparados Tamarit Pérez; J L Hontangas Lopez; S Viviani
Journal:  Acta Paediatr       Date:  2003-05       Impact factor: 2.299

9.  Antibody to Haemophilus influenzae type b after routine and catch-up vaccination.

Authors:  C L Trotter; J McVernon; N J Andrews; M Burrage; M E Ramsay
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

Review 10.  Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.

Authors:  Ron Dagan; Jan T Poolman; Fred Zepp
Journal:  Expert Rev Vaccines       Date:  2008-02       Impact factor: 5.217

View more
  5 in total

1.  Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.

Authors:  Julia Hutter; Marcela F Pasetti; Doh Sanogo; Milagritos D Tapia; Samba O Sow; Myron M Levine
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b.

Authors:  Han Wool Kim; Kyung-Hyo Kim; JiHye Kim; Moon H Nahm
Journal:  BMC Infect Dis       Date:  2016-09-05       Impact factor: 3.090

3.  Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Authors:  Sonu Shrestha; Lisa K Stockdale; Madhav C Gautam; Meeru Gurung; Shuo Feng; Pratistha Maskey; Simon Kerridge; Sarah Kelly; Merryn Voysey; Bhishma Pokhrel; Piyush Rajbhandari; Stephen Thorson; Bibek Khadka; Ganesh Shah; Karin S Scherer; Dominic Kelly; David R Murdoch; Shrijana Shrestha; Andrew J Pollard
Journal:  J Infect Dis       Date:  2021-09-01       Impact factor: 5.226

4.  The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.

Authors:  Andrew S J Marshall; Charlotte I S Barker; Anoop S Pulickal; Elizabeth Kibwana; Samir C Gautam; Elizabeth A Clutterbuck; Stephen M Thorson; Shrijana Shrestha; Neelam Adhikari; Andrew J Pollard; Dominic F Kelly
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

5.  Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study.

Authors:  Laura L Hammitt; Rosie J Crane; Angela Karani; Alex Mutuku; Susan C Morpeth; Polly Burbidge; David Goldblatt; Tatu Kamau; Shahnaaz Sharif; Neema Mturi; J Anthony G Scott
Journal:  Lancet Glob Health       Date:  2016-02-05       Impact factor: 38.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.